Zura Bio (NASDAQ:ZURA) outlined its near-term clinical milestones and strategy at Guggenheim Securities’ Emerging Outlook Biotech Summit 2026, emphasizing upcoming Phase 2 readouts for its lead ...
The MarketWatch News Department was not involved in the creation of this content. US Rheumatologists Identify BAFF-R Inhibitors as the Most Promising Treatment Approach for Sjögren's Disease, ...
BRISBANE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative ...
NEW YORK and WALTHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to ...
Clinicians face exciting new options in immunoglobulin A (IgA) nephropathy, with recent accelerated FDA approvals and positive data presented on agents targeting B-cell activating factor (BAFF) and a ...
Tickling Wall Street’s already strong interest in the mechanism of action was Aurinia Pharmaceuticals Inc., which June 30 made public positive results from the phase I single ascending-dose study with ...
DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results